User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.

Primary tabs

Godfraind, Catherine [UCL] Rousseau, Emmanuel [UCL] Ruchoux, M-M Scaravilli, F. Vikkula, Miikka [UCL]

A subset of oligodendrogliomas and oligoastrocytomas has been associated with 1p/19q deletion. Subsequently, this genetic alteration was linked to chemosensitivity and classic histology of oligodendrogliomas. Tumoural progression includes deletions of 9p, 10q and alterations of CDKN2A. However, these (epi)genetic changes have not been associated with specific histological features. In a series of 45 gliomas including oligodendrogliomas, oligoastrocytomas and astrocytomas, deletions of chromosomal regions implied in these tumours (1p, 9p, 10, 17p13, 19q and 22) were looked for by microsatellite analysis. Tumours that were deleted for 1p and 19q were selected. Subsequently, presence of deletions in the other studied regions, (epi)genetic changes in p14ARF, CDKN2A and CDKN2B, as well as histological features, were associated to these tumours. 1p/19q deletion was observed in 22 tumours. Twenty-one of them presented regions of classic histology of oligodendroglioma. A deletion of 9p was found in eight of them, always in association with tumour necrosis and/or microvascular proliferation. In addition, (epi)genetic alterations of CDKN2A were observed in 71% of these tumours. Presence of regions of classic histology of oligodendroglioma in a tumour sample is predictive of 1p/19q deletions. Necrosis and/or microvascular proliferation are signs of an additional 9p deletion. Finally, as CDKN2A (epi)genetic alterations were found in 71% of the 1p/19q/9p-deleted oligodendrogliomas, CDKN2A may have a role in oligodendroglioma-associated microvascular proliferation.

  1. Kleihues P, Pathology & Genetics. Tumours of the Nervous System (2000)
  2. Reifenberger J, Am J Pathol, 145, 1175 (1994)
  3. Kraus JA, J Neuropathol Exp Neurol, 54, 91 (1995)
  4. Maintz D, J Neuropathol Exp Neurol, 56, 1098 (1997)
  5. Jeuken Judith W. M., Sprenger Sandra H. E., Boerman Rudolf H., von Deimling Andreas, Teepen Hans L. J. M., van Overbeeke Jacobus J., Wesseling Pieter, Subtyping of oligo-astrocytic tumours by comparative genomic hybridization, 10.1002/path.837
  6. Cairncross J. Gregory, Ueki Keisuke, Zlatescu Magdelena C., Lisle David K., Finkelstein Dianne M., Hammond Robert R., Silver Jonathan S., Stark Paul C., Macdonald David R., Ino Yasushi, Ramsay David A., Louis David N., Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas, 10.1093/jnci/90.19.1473
  7. Sasaki Hikaru, Zlatescu Magdalena C., Betensky Rebecca A., Johnk Loki B., Cutone Andrea N., Cairncross J. Gregory, Louis David N., Histopathological-Molecular Genetic Correlations in Referral Pathologist-Diagnosed Low-Grade “Oligodendroglioma”, 10.1093/jnen/61.1.58
  8. Coons Stephen W., Johnson Peter C., Scheithauer Bernd W., Yates Allan J., Pearl Dennis K., Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas, 10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w
  9. Burger PC, Mod Pathol, 14, 842 (2001)
  10. Ruas Margarida, Peters Gordon, The p16INK4a/CDKN2A tumor suppressor and its relatives, 10.1016/s0304-419x(98)00017-1
  11. Bortolotto Simona, Chiad�-Piat Loredana, Cavalla Paola, Bosone Ivana, Chi� Adriano, Mauro Alessandro, Schiffer Davide, CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas, 10.1002/1097-0215(20001115)88:4<554::aid-ijc6>3.0.co;2-q
  12. Wolter Marietta, Reifenberger Julia, Blaschke Britta, Ichimura Koichi, Schmidt Esther E., Collins V. Peter, Reifenberger Guido, Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of theCDKN2A(MTS1, p16INK4a),p14ARF, andCDKN2B(MTS2,p15INK4b) Tumor Suppressor Genes, 10.1093/jnen/60.12.1170
  13. Watanabe T, Acta Neuropathol (Berl), 101, 185 (2001)
  14. Watanabe Takao, Yokoo Hideaki, Yokoo Minako, Yonekawa Yasuhiro, Kleihues Paul, Ohgaki Hiroko, Concurrent Inactivation of RB1 and TP53 Pathways in Anaplastic Oligodendrogliomas, 10.1093/jnen/60.12.1181
  15. Dong Shu-min, Pang Jesse Chung-sean, Poon Wai-sang, Hu Jie, To Ka-fai, Chang Alexander Russell, Ng Ho-keung, Concurrent Hypermethylation of Multiple Genes Is Associated with Grade of Oligodendroglial Tumors, 10.1093/jnen/60.8.808
  16. Mao L, Cancer Res, 55, 2995 (1995)
  17. Hussussian CJ, Nat Genet, 8, 15 (1994)
  18. Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands., 10.1073/pnas.93.18.9821
  19. Esteller M, Cancer Res, 60, 129 (2000)
  20. Zhang L, Proc Natl Acad Sci USA, 89, 5847 (1992)
  21. Wong DJ, Cancer Res, 57, 2619 (1997)
  22. Burger PC, Surgical Pathology of the Nervous System and its Coverings (2002)
  23. Graham DI, Greenfields Neuropathology (2002)
  24. Ironside JW, Diagnostic Pathology of Nervous System (2002)
  25. von Deimling A, Glia, 15, 328 (1995)
  26. Louis David N., Holland Eric C., Cairncross J. Gregory, Glioma Classification, 10.1016/s0002-9440(10)61750-6
  27. Bigner Sandra H., Matthews Mark R., Rasheed B.K.A., Wiltshire Rodney N., Friedman Henry S., Friedman Allan H., Stenzel Timothy T., Dawes Donald M., McLendon Roger E., Bigner Darell D., Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic Hybridization, 10.1016/s0002-9440(10)65134-6
  28. Smith Justin S., Tachibana Issei, Lee Hyun K., Qian Junqi, Pohl Ute, Mohrenweiser Harvey W., Borell Thomas J., Hosek Sandra M., Soderberg Cheryl L., von Deimling Andreas, Perry Arie, Scheithauer Bernd W., Louis David N., Jenkins Robert B., Mapping of the chromosome 19 q‐arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers, 10.1002/1098-2264(2000)9999:9999<::aid-gcc1007>3.3.co;2-9
  29. Kros Johan M., Hop Wim C. J., Godschalk Josiane J. C. J., Krishnadath Kausilia K., Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas, 10.1002/(sici)1097-0142(19960901)78:5<1107::aid-cncr22>3.0.co;2-5
  30. Harada H, Cancer Res, 59, 3783 (1999)
  31. Varlet P., Guillamo J. S., Nataf F., Koziak M., Beuvon F., Daumas-Duport C., , Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study withSainte-Anne malignancy grade, growth fractionand patient survival, 10.1046/j.1365-2990.2000.00263.x
  32. Chaudhry I H, O'Donovan D G, Brenchley P E C, Reid H, Roberts I S D, Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas, 10.1046/j.1365-2559.2001.01230.x
  33. Christov, Christov, Adle-Biassette, Adle-Biassette, Le Guerinel, Le Guerinel, Natchev, Gherardi, Gherardi, Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas, 10.1046/j.1365-2990.1998.00091.x
  34. Chan Annie S.Y., Leung Suet Yi, Wong Maria P., Yuen Siu Tsan, Cheung Ngai, Fan Yiu Wah, Chung Lap Ping, Expression of Vascular Endothelial Growth Factor and Its Receptors in the Anaplastic Progression of Astrocytoma, Oligodendroglioma, and Ependymoma : , 10.1097/00000478-199807000-00004
  35. Alvarez JA, Mod Pathol, 5, 303 (1992)
  36. Sasaki Hikaru, Zlatescu Magdalena C., Betensky Rebecca A., Ino Yasushi, Cairncross J. Gregory, Louis David N., PTEN Is a Target of Chromosome 10q Loss in Anaplastic Oligodendrogliomas and PTEN Alterations Are Associated with Poor Prognosis, 10.1016/s0002-9440(10)61702-6
Bibliographic reference Godfraind, Catherine ; Rousseau, Emmanuel ; Ruchoux, M-M ; Scaravilli, F. ; Vikkula, Miikka. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.. In: Neuropathology and applied neurobiology, Vol. 29, no. 5, p. 462-471 (2003)
Permanent URL http://hdl.handle.net/2078.1/9633